Did you know that top cancer centers across the United States work together to improve cancer care? This alliance of leading cancer centers is called the National Comprehensive Cancer Network® (NCCN®).

Cancer care is always changing. NCCN develops evidence-based cancer care recommendations used by health care providers worldwide. These frequently updated recommendations are the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines for Patients plainly explain these expert recommendations for people with cancer and caregivers.

These NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, Version 4.2024 — May 17, 2024.

View the NCCN Guidelines for Patients free online
NCCN.org/patientguidelines

Find an NCCN Cancer Center near you
NCCN.org/cancercenters
NCCN Guidelines for Patients are supported by funding from the NCCN Foundation®

NCCN Foundation gratefully acknowledges the following supporters for helping to make available these NCCN Guidelines for Patients: Astellas, and Janssen Biotech, Inc.

NCCN independently adapts, updates, and hosts the NCCN Guidelines for Patients. Our corporate supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein.

To make a gift or learn more, visit online or email

NCCNFoundation.org/donate  PatientGuidelines@NCCN.org
Contents

4 Prostate cancer basics
12 Tests for advanced prostate cancer
24 Prostate cancer treatments
37 Regional prostate cancer treatment options
45 Metastatic prostate cancer treatment options
56 Supportive care and other assistance
62 Making treatment decisions
74 Words to know
76 NCCN Contributors
77 NCCN Cancer Centers
80 Index
1 Prostate cancer basics

5 What is prostate cancer?
6 What are the symptoms of prostate cancer?
6 What causes prostate cancer?
10 What is advanced-stage prostate cancer?
10 Can prostate cancer be cured?
11 What’s the best treatment?
11 Key points
The prostate is a gland located deep inside the pelvis. Everyone with a prostate has a chance of getting prostate cancer. This chapter offers an overview of this common cancer.

What is prostate cancer?

Prostate cancer is a disease where cells in the prostate gland grow out of control.

The prostate is a gland located just below the bladder in the pelvis, deep inside the area of your body between your hip bones. The prostate is an important part of the male reproductive system. Besides the prostate, the male reproductive system includes the penis, seminal vesicles, and testicles.

Prostate cancer is one of the most common types of cancer. Cancer is what happens when something goes wrong with the natural cell process, which causes some cells to grow out of control.

Cancer cells don’t behave like normal cells. Cancer cells develop genetic changes (mutations) that allow them to multiply and make many more cancer cells. The cancer cells crowd out and overwhelm normal cells. This can end up harming the body.

Cancer cells can survive much longer than normal cells do. They can replace many normal cells and cause organs to stop working well. Cancer cells can also spread outside the prostate to other areas of the body.

The prostate gland is an important part of the male reproductive system. It’s located in the pelvis just below the bladder and is typically about the size of a ping-pong ball.
What are the symptoms of prostate cancer?

A symptom is a feeling or problem that can indicate a disease or condition. Prostate cancer often grows slowly and shows no symptoms for a long time. You don’t have to have symptoms to have prostate cancer.

Symptoms, if they occur, may include:

- Blood in the urine or semen
- Burning or pain while urinating
- Unexplained weight loss
- Bone, hip, or back pain
- Feeling like your bladder hasn’t fully emptied
- Dull pain in your groin or pelvis
- Erectile dysfunction (difficulty getting an erection) or painful ejaculation

What causes prostate cancer?

Many people who develop prostate cancer wonder where it came from and how they got it. Cancer researchers don’t know exactly what causes prostate cells to grow out of control (become cancerous). The fact is, everyone with a prostate has a risk of getting prostate cancer.

But several factors are linked to a higher risk of prostate cancer. These are called risk factors. A risk factor is anything that increases your chance of getting cancer. Risk factors don’t necessarily cause prostate cancer, but people with prostate cancer usually have one or more of these risk factors:

**Age**

The biggest risk factor for prostate cancer is age. Prostate cancer is diagnosed most often in those aged 65 years and above. Your chances of getting prostate cancer increase as you become older.

**Family history**

Your family health history is information about the diseases and health conditions in your family. A family history reflects a pattern of certain diseases among family members.
Where does the prostate fit in?

The prostate is a gland located in the pelvis—the area between your hips. The prostate is important for sexual reproduction.

**Prostate:** A gland in the male reproductive system. A gland is an organ that makes fluids or chemicals the body needs. The prostate gland makes a fluid that nourishes and helps transmit sperm. The prostate also contains muscles that help propel semen through the urethra during ejaculation.

**Semen:** A fluid made up of liquids from the prostate and the seminal vesicles as well as sperm from the testicles. During ejaculation, semen is released from the body through the urethra and out through the penis.

**Urethra:** A tube that carries urine from the bladder and out of the body. The prostate surrounds the urethra just beneath the bladder.

**Seminal vesicles:** Two glands that make and store another part of the fluid that becomes semen. The seminal vesicles are located above the prostate and behind the bladder.

**Bladder:** An organ that holds urine.
Having a close family member with prostate cancer (a sibling or parent) increases the chance of getting it yourself. Those with a family history of certain other cancers (breast, ovarian, colon, pancreatic, and other cancers) may also be at higher risk for prostate cancer.

**Genetic factors**

When cancer “runs in the family,” genetic testing can be done to find specific genetic changes (mutations) known to be linked with prostate cancer and other cancers. For instance, having an inherited genetic change in the BRCA2 gene increases the risk of getting prostate cancer.

There are also genetic abnormalities that don’t run in families and aren’t inherited.

**Race**

In the United States, Black males are more likely than white males to develop prostate cancer. Prostate cancer in Black males is also more likely to occur at an earlier age and be more aggressive and more advanced when diagnosed. Black males are also twice as likely to die from prostate cancer compared to white males.

Hispanic and Asian males are less likely than both white and Black males to be diagnosed with prostate cancer.

Several things contribute to these differences, such as barriers to accessing health care (including early detection screening), as well as biological and genetic factors, and other causes. Researchers are trying to understand the reasons for these differences and what can be done to improve outcomes.

**What does aggressive mean?**

When health care professionals describe cancer as aggressive, they mean the cancer is likely to grow or spread more rapidly than average.

Aggressive can also be used to describe therapy that may be stronger or more intense than other treatment options.

Black males may want to talk with their health care providers about getting screening tests earlier and perhaps more often than what’s recommended for other males.

**Diet and lifestyle**

No one particular diet has been found to cause prostate cancer or to prevent it. However, eating food that’s high in fat, such as meat and dairy products, has been linked with an increased risk of prostate cancer. Smoking and obesity also increase the risks of developing and dying from prostate cancer.

On the other hand, those who eat more fruits and vegetables have a lower risk of developing advanced prostate cancer. Exercise and maintaining a healthy weight may also decrease the aggressiveness of prostate cancer and the likelihood of dying from it.
Early vs. advanced prostate cancer

**Early-stage prostate cancer** has not visibly spread beyond the prostate. It usually grows slowly and stays in the prostate. This is also called localized prostate cancer.

**Advanced-stage prostate cancer** has grown outside the prostate and spread to other areas in the body such as distant lymph nodes (bottom left), bones, or organs like the liver or lungs (bottom right). This is also called metastatic prostate cancer.
What is advanced-stage prostate cancer?

Prostate cancer can be grouped into early-stage cancer or advanced-stage cancer.

Early stage

Early-stage prostate cancer has not spread beyond the prostate. The cancer usually grows slowly and stays in the prostate. Cancer that is contained entirely within the prostate is called localized prostate cancer.

More information about early-stage prostate cancer can be found in the NCCN Guideline for Patients: Early-Stage Prostate Cancer at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.

Advanced stage

Advanced stage means that the cancer has spread beyond the prostate to other areas in the body. This spreading is called metastasis or metastatic cancer. Metastatic prostate cancer may spread to the lymph nodes, bones, liver, lungs, and other organs.

This book is all about advanced-stage prostate cancer.

- Cancer that spreads beyond the prostate to other parts of the body is called distant metastatic prostate cancer or simply metastatic prostate cancer.

How does prostate cancer spread? Cancer cells use the bloodstream like a highway to travel to distant areas in the body. Cancer cells can also spread through the lymphatic system. The lymphatic system is a network of organs and vessels that fights infections and circulates a clear fluid called lymph throughout the body.

A normal and important part of the lymphatic system are the lymph nodes. Lymph nodes are small, disease-fighting clusters that filter lymph fluid to remove germs. Lymph vessels and nodes are found everywhere in the body.

Some patients have advanced-stage prostate cancer when they’re first diagnosed. Others develop advanced-stage cancer after having treatment for early-stage cancer.

Can prostate cancer be cured?

Advanced-stage prostate cancer is usually a life-long disease. But treatment can slow down its growth, reduce symptoms, and prolong life. Treatments for advanced-stage prostate cancer include hormone therapy, chemotherapy, radiation therapy, immunotherapy, targeted therapy, radiopharmaceuticals, surgery, and other therapies.

It’s true that prostate cancer in the advanced stage can be fatal for some patients. But in the past few years, improved detection methods
and better treatments have been reducing the number of deaths from prostate cancer in patients of all races and ethnicities. Many people with advanced-stage prostate cancer continue to live with the cancer and, in the end, may die from something else.

Scientists have learned a great deal about prostate cancer in recent years. As a result, today's detection methods and treatments work better than those in the past. Also, many patients with prostate cancer have more treatment choices now than they had before.

**What’s the best treatment?**

The best treatment for prostate cancer is the treatment that's right for you. Your team will work with you to figure out the therapies that have the best chance for fighting your particular cancer.

Importantly, your team should follow best practices. This book is based on the best practices for treating advanced-stage prostate cancer. Best practices come from the latest research and methods at top cancer centers. Your treatment team should personalize your care following the best practices.

Many new tests and treatments are now available for advanced prostate cancer. If possible, seek care or a second opinion from a medical center that specializes in prostate cancer.

**Key points**

- Prostate cancer develops when cells in the prostate gland grow out of control.
- Age is the leading risk factor for prostate cancer. As you age, your chances of developing prostate cancer increase.
- Having a close family member with prostate cancer means that you have a higher chance of getting it yourself.
- Everyone with a prostate is at risk for prostate cancer. Black people and people with certain inherited genetic mutations are at greater risk.
- Advanced-stage prostate cancer has spread outside the prostate to other areas in the body. This spreading is called metastasis.
- Advanced-stage prostate cancer is usually a life-long disease. Treatment can slow it down, reduce its symptoms, and help people live longer.
2

Tests for advanced prostate cancer

13  Common prostate tests
14  General health history
15  Diagnostic tests
20  Genetic tests
22  Tumor staging
23  What’s next?
23  Key points
If you haven’t yet been diagnosed with prostate cancer, you may need multiple tests and scans to find out if you have it and whether it has spread. These tests and scans will help your team make the best plan to treat your prostate cancer.

Health care providers use a variety of tests to find prostate cancer and to determine how advanced the cancer is. Tests are used to plan treatment, check how well treatment is working, and monitor your health after treatment ends. This chapter describes what tests you might have and what to expect during testing. Not every person with prostate cancer will receive every test listed here.

When you go for testing, bring someone with you to listen, ask questions, and write down the answers.

Common prostate tests

Common prostate cancer tests are used to detect the possibility of prostate cancer in someone who’s undiagnosed. They’re also used to check and monitor prostate cancer in patients who have been diagnosed.

Two common tests that look for prostate cancer are the PSA test and digital rectal exam.

PSA test

This is a blood test that measures the amount of prostate-specific antigen (PSA) in your bloodstream. PSA is a protein made inside the prostate gland. Its job is to help semen transport sperm. All prostate cells, both normal cells and cancer cells, make PSA.

If there’s something wrong with the prostate—like prostate cancer—the prostate may make more PSA. While most PSA goes into semen, a little bit ends up in the bloodstream, too. An unusually high amount of PSA in the blood may be a sign of prostate cancer. Likewise, an increase in PSA after treatment may indicate that the treatment is losing effectiveness.

However, age and other factors—such as an enlarged prostate or a urinary tract infection—can also cause high levels of PSA. This means that a PSA test by itself can’t provide a diagnosis of prostate cancer. That’s why a PSA test is often paired with imaging or a digital rectal exam, or both, to decide whether you need a biopsy.

PSA level (also called total PSA) is measured in nanograms of PSA per milliliter (ng/mL) of blood.

Digital rectal exam

A digital rectal exam (also called a prostate exam) may be an awkward and unpleasant form of testing. But it’s the simplest and most direct way to check the size and texture of your prostate.

For this test, the doctor will insert a gloved finger into your rectum to feel your prostate for any signs of cancer. An irregular or hardened part of the prostate could be a sign of a tumor.
Not all parts of the prostate can be felt during a digital rectal exam, though. So it’s usually paired with a PSA test and other factors—your age, race, family history, and more—to determine whether you need further testing.

General health history

Health history and physical exam

Your care team needs to have all your health information. They’ll ask you about any health problems and treatments you’ve had in your life. Be prepared to talk about any illness or injury you’ve had and when it happened. Also tell your team about any symptoms you have.

Bring a list of your regular medications and any over-the-counter medicines, herbs, or supplements you take. Some of these (such as saw palmetto or St. John’s wort) can cause changes in your PSA level, so your care team needs to know if you’re taking them.

A physical exam is a check of your body for any signs of disease. Your health care provider may feel for enlarged glands (lymph nodes) in your groin, underarms, and neck.

Family history

Some cancers and other diseases can run in families. Your care team will ask about the health history of family members who are blood relatives. This information is called a family history.

It’s important to ask members from both sides of the family about all cancers, not just prostate cancer. Ask family members if any relatives had cancer, at what age they were diagnosed, and if they died from it. Also ask family members about other health issues like heart disease, stroke, and diabetes. Share this information with your care team and update your team with any changes to your family history.

Symptoms and quality of life

Your doctor or another member of your care team will ask you a series of questions about what symptoms you may have (such as peeing...
frequently, difficulty peeing or pooping, or sexual problems). You’ll also be asked how these symptoms affect your quality of life.

Quality of life refers to your overall satisfaction with your well-being and your ability to participate in regular activities. It’s important to answer all these questions honestly and completely so your care team has full and up-to-date information about how you’re doing.

Diagnostic tests

Diagnostic tests are used to confirm you have cancer. They’re also used to find out if the cancer is localized or advanced. Diagnostic tests can help plan treatment after you’ve been diagnosed and can detect whether the cancer is still growing or spreading after treatment.

Diagnostic tests include imaging scans, biopsies, and genetic tests.

Imaging tests

An imaging test takes pictures (images) of the insides of your body. The images can reveal cancer, including its size, location, and other features such as the size of the prostate itself. The images may show where the cancer started (primary tumor) and whether the cancer has spread (metastasized).

After your scan, your images will be studied by a radiologist. A radiologist is a doctor who’s an expert in reading imaging tests. The radiologist will send the results to your care team. This information helps to plan the next steps of your care. Your team will discuss the results with you. Be sure to ask any questions you may have.

Imaging can come before, during, or after a biopsy. Imaging may also be used after cancer treatment to see how well it worked and to check if the cancer comes back.

Imaging methods for prostate cancer include MRI, CT, PET, ultrasound, bone scan, or a combination of these.

MRI scan

A magnetic resonance imaging (MRI) scan uses radio waves and powerful magnets to take pictures of the inside of the body. An MRI can be used to get a more detailed view of the cancer within the prostate. It’s also used to see if cancer has spread to nearby lymph nodes or to the bones in your pelvis.

MRI scans can also help to plan treatment, and may be used after treatment to

Diagnosis vs. prognosis

What’s the difference between your diagnosis and your prognosis? These two words sound alike but they’re very different.

**Diagnosis** is identifying an illness based on tests. Your diagnosis names what illness you have.

**Prognosis** is the likely course and outcome of a disease. Your prognosis predicts how your illness will turn out.
check whether the cancer has come back (recurrence).

An appointment for an MRI scan can take 1 to 2 hours, including 30 to 60 minutes of actual scanning time. You’ll need to remain as motionless as possible during each scan. You may be positioned with pillows or bolsters to help you keep still.

Because an MRI uses magnets, you can’t bring any metal objects (such as jewelry, phones, wristwatches, or belts with metal buckles) into the imaging room.

**CT scan**
A computed tomography (CT or CAT) scan uses x-rays and computer technology to take pictures of the inside of the body. CT takes many x-rays of the same body part from different angles. The computer combines all the x-ray pictures to make a single detailed image. A CT scan is usually completed in less than 30 minutes.

**PET scan**
A positron emission tomography (PET) scan highlights cells in your body that may be cancerous. You may have a PET scan after you’ve been diagnosed to determine the extent of your cancer or to see if it has metastasized. PET imaging can also show how well treatment is working.

A PET scan requires injecting a radioactive substance called a tracer into your bloodstream. It takes about an hour for the tracer to circulate throughout your body. The tracer targets your cancer cells, which show up as bright spots on the scan. Afterward, the radiotracer is passed out of your body in your urine.

A PET scan appointment can take 1 to 2 hours, including about 30 minutes of actual scanning time.

Because PET uses a different imaging method, it’s often combined with other types of imaging, such as CT or MRI, to provide an even more detailed view of the cancer.

**PET imaging**
A positron emission tomography (PET) scan highlights cells in your body that may be cancerous. A PET scan can determine the extent of your cancer or see if it has metastasized. PET imaging can also show how well treatment is working.
Tests for advanced prostate cancer  » Diagnostic tests

PSMA-PET
PET scans use different types of tracers. The most common tracer in prostate cancer locates a protein called prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells. Prostate cancer cells can make a lot of PSMA, so doctors developed tracers that target this specific protein.

Not everyone with prostate cancer will need a PSMA-PET scan. It’s mostly used to monitor prostate cancer for recurrence. It’s also used to determine whether targeted therapy can treat certain cases of metastatic prostate cancer.

Bone scan
A bone scan can detect whether cancer has spread to your bones. A bone scan may be used if you have bone pain, have a high risk for bone metastasis, or have changes in certain test results. Bone scans may also be used to monitor treatment.

A bone scan uses a radioactive tracer to make pictures of the inside of bones. Before the pictures are taken, the tracer is injected into your bloodstream. It can take a few hours for the tracer to enter your bones.

A special camera will take pictures of the tracer in your bones. Areas of bone damage absorb more tracer than healthy bone. These areas show up as bright spots in the scans.

Ultrasound
Ultrasound imaging is commonly used to help guide a biopsy of the prostate. This is called transrectal ultrasound (TRUS) imaging.

During a biopsy, an ultrasound probe is inserted into the rectum. The probe is about the size of a finger. The device uses high-energy sound waves to create a view of the prostate from inside the body. These images allow the surgeon to remove a small sample of the prostate without having to open up your abdomen.

### PET/CT scan of prostate cancer

This image combines PET and CT scans to show a cross-section of a patient’s pelvis. The greenish circle identifies cancer in the prostate, while the intense red dot indicates cancer that has spread to a lymph node in the pelvis.
At some centers, your saved MRI images can be combined with real-time ultrasound to provide a more detailed view for a more precise biopsy. This is called MRI-TRUS fusion.

**Biopsy**
A biopsy is a procedure in which a sample of cells, fluid, or tissue is removed from your body and tested for cancer. It’s the main way to confirm whether you have cancer.

A biopsy is an invasive test, which means that it goes into (invades) your body. All invasive tests have some risk. The risks for a prostate biopsy include infection, bleeding, and pain. Doctors use invasive tests only when needed. You and your care team will decide when, or if, you need a biopsy.

A biopsy sample may be taken from the prostate, the metastasis (an area of cancer that has spread outside of the prostate), or sometimes both.

**Biopsy of the prostate**
A prostate biopsy is usually performed by a urologist. A urologist is a doctor who’s an

---

**PSMA-PET scan of prostate cancer**
A CT scan for a patient treated for prostate cancer shows a cross-section of the body at the pelvis. The CT pinpoints a lymph node that appears normal (top image).

But a PMSA-PET scan of the same lymph node highlights prostate cancer cells (arrow in bottom image).

Images: University of Chicago Medicine
expert in treating diseases of the urinary system and the male reproductive organs.

For this procedure, you’ll lie on your side with your knees curled up or you’ll lie on your back with your legs raised. You’ll be given anesthesia to numb the pain or to make you fall asleep. The urologist will insert a lubricated probe into your rectum. The probe provides a visual image of the prostate.

The urologist will then insert a hollow needle into the prostate gland using the video display to guide it. The needle is inserted either through the perineum (the skin between the anus and scrotum) or through the rectum.

When the urologist removes the needle, it will pull out a small sample of prostate tissue called a core. A core sample is only about 1 to 2 millimeters wide and 12 to 20 millimeters long—about as wide as a toothpick and as long as a raisin. The urologist will usually take 12 or more core samples from different parts of the prostate. Checking different areas provides a more complete evaluation of cancer throughout the gland.

After the biopsy samples are removed, a specialist called a pathologist will examine the samples under a microscope and test them for cancer cells. The pathologist will find out how many of the core samples contain cancer and will also measure the percentage of cancer in each core.

With this information, the pathologist can estimate the amount of cancer in the prostate and how aggressive it may be. Also, by knowing where each core sample was taken, the pathologist can tell if the cancer is concentrated in a certain section of the prostate.

The pathologist will put these results into a report. Ask your doctor or another member of

---

**Biopsy of the prostate**

A biopsy removes a sample of tissue that is tested for cancer. This is a transperineal biopsy, in which a needle is inserted through the perineum and into the prostate. An ultrasound probe, which goes into the rectum, helps the doctor guide the needle into the prostate. MRI scans of your prostate may be combined with the ultrasound image to provide a highly accurate picture of the cancer.
your care team to review the pathology report with you.

**Biopsy of the metastasis**
A biopsy of a metastasis can be taken from a lymph node, an internal organ, or a bone. This biopsy is performed in a similar way to a prostate biopsy—using a hollow needle to remove cores of tissue.

Sometimes, a blood sample is taken, also called a “liquid biopsy,” to look for cancer cells in the blood.

Having a biopsy may cause complications. A complication is an unwanted and unplanned result from a procedure. Complications may include infection, bleeding from the rectum, or blood in the urine, stool, or semen. These usually go away after a few days or, with semen, after a few weeks. It’s also important to know that a biopsy won’t cause prostate cancer to spread or worsen.

**Genetic tests**
A genetic test is used to find harmful changes in your genes. Genes are small segments of DNA inside every cell. Genes provide the instructions to tell the cell how to make proteins, which carry out a lot of important functions in the body.

Once in a while, a gene will have or develop a change, called a mutation, that damages its function. As a result of this mutation, the gene isn’t able to make a normal protein so the protein can’t do its necessary job. This can affect the usual activities of the cell, which can lead to disease, such as cancer.

Mutations can be passed down in families, in which case they occur in every cell in your body. Or mutations can occur spontaneously in just some of your cells. In other words, they may be in your body before you’re born (called a hereditary or germline mutation) or occur by
chance or environmental factors later in life (called an acquired or somatic mutation).

The two basic types of genetic tests used for prostate cancer care are hereditary gene testing and tumor testing:

**Hereditary gene testing**

Sometimes, mutations in genes inherited from your parents can increase the risk of different cancers. You can pass these genes on to your children. Your siblings or other family members might also carry these mutations. If you have a family history of cancer, your health care provider might suggest genetic testing to find out if you have an inherited cancer risk. This is also called germline testing.

The goal of this type of genetic testing is to look for inherited (germline) mutations that occur in every cell in your body. Genetic germline testing is done using a sample of your blood, urine, or saliva.

For prostate cancer, this testing typically looks for characteristic changes in these genes: BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, and others.

Having a hereditary mutation doesn’t mean you’ll automatically get cancer. It means your chances for developing certain cancers is higher.

Some mutations can put you at risk for more than one type of cancer. Inherited mutations in genes like BRCA1 or BRCA2 are also related to breast cancer, ovarian cancer, pancreatic cancer, and skin cancer (melanoma). Inherited mutations in MSH2, MSH6, MLH1, and PMS2 are related to colorectal cancer, uterine cancer, and other cancers in addition to prostate cancer.

If an inherited cancer risk gene is suspected based on your family’s or your own health history, you should ask about genetic testing. Your health care provider can talk to you about testing or refer you to a genetic counselor. A genetic counselor is an expert who has special training in genetic diseases. A genetic counselor can help you decide whether you would like to undergo germline testing and also help you interpret the results of these tests.

Inherited gene testing is recommended if you have prostate cancer and any of the following:

- Family members or relatives who have or had prostate cancer, breast cancer, ovarian cancer, intestinal cancer, and certain other cancers
- Family history of mutations in certain genes including BRCA1, BRCA2, ATM, CHEK2, and others
- Very-high-risk, high-risk, regional (cancer in a lymph node), or metastatic prostate cancer regardless of family history
- Ashkenazi Jewish ancestry

Talk to your medical providers and/or a genetic counselor about your family history of cancer.

**Tumor testing**

Tumor testing (also called somatic testing, molecular tumor testing, or tumor profiling) requires a tissue sample from the tumor itself or from a metastasis in a lymph node, bone, liver, lung, or other affected area. Or it may come a sample of your blood, which contains the tumor’s DNA.
In this type of testing, the sample is analyzed to look at its molecular components. Tumors often release molecules that can be used as clues for finding and learning about the cancer. This information helps figure out the likelihood that your cancer could spread to other parts of the body. It can also help predict whether the cancer could transform into a more aggressive type.

Importantly, targeted therapies (PARP inhibitors, for example) can be used against cancers that have particular molecular tumor markers. So the testing looks for specific abnormalities in a number of genes involved in DNA repair, including BRCA1, BRCA2, ATM, PALB2, FANCA, and others.

## Tumor staging

Tumors come in different shapes and sizes. So it’s not easy to compare one tumor to another. To solve this problem, cancer experts created the tumor, node, metastasis (TNM) system to describe any tumor. It’s based on the results of your imaging scans, biopsies, and blood tests.

In this system, the letters T, N, and M stand for different areas of cancer growth:

- **T (tumor)** – Describes the size of the main (primary) tumor and if it has grown outside the prostate
- **N (node)** – Identifies whether cancer has spread to lymph nodes
- **M (metastasis)** – Indicates if cancer has spread (metastasized) to parts of the body outside of the pelvis

Your provider will assign a number to each letter, based on your test results. The higher the number, the larger the tumor (T) or the more the cancer has spread (M). These scores are combined to assign a “stage” to the cancer.

Staging is a way to describe how much cancer is in your body and how far it has spread. Knowing your stage is important for predicting the course of your disease and for making a treatment plan.

Cancer staging is done when you’re first diagnosed. It may also be done after treatment to confirm that the stage hasn’t changed.

### How to read a TNM score

Let’s say your prostate cancer is given a TNM score of **T4, N1, M1**. This score means that the tumor has grown outside the prostate gland (T4) and has spread to nearby lymph nodes (N1) and to one or more distant parts of the body (M1).

Why know your TNM score? For one, it lets you know the extent of your cancer. It also helps characterize your risk for the cancer to spread. Your level of risk helps indicate the most appropriate treatment for you.
Measurements and assessments not covered in this book include PSA density, Gleason score, Grade Group, and risk groups. To learn more about these, see the NCCN Guidelines for Patients: Early-Stage Prostate Cancer, which can be found at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.

What’s next?

After you’ve had all these tests to confirm you have prostate cancer, your care team will discuss your test results and will work with you to develop a plan for treatment.

The next chapter describes the different treatment options for advanced-stage prostate cancer. After that chapter, you’ll read about which of those treatments may be right for you and your particular type of cancer.

Key points

- Tests are used to plan treatment and check how well treatment is working.
- An unusually high amount of PSA in the bloodstream may be a sign of prostate cancer.
- Imaging tests are used to see where the cancer has spread beyond the prostate. Imaging also shows the size and location of the cancer.
- A biopsy is a procedure that removes samples of cells or tissue, which are tested for cancer.
- A genetic test is used to find abnormal changes (mutations) in your genes.
- An inherited genetic mutation occurs in every cell in your body. A somatic mutation occurs all by itself and is only found in the cells of a tumor.
- To find out if you have an inherited risk for cancer, talk to your doctor about germline testing or ask to be referred to a genetic counselor.
Prostate cancer treatments

25 Hormone therapy
29 Non-hormone therapy
32 Clinical trials
34 Supportive care
36 What’s next?
36 Key points
There’s more than one treatment for advanced prostate cancer. This chapter describes the available treatment options and what you might expect from them. Talk with your care team about which treatment could be best for you.

Prostate cancer is a complex disease with many treatment options. Treatments for advanced-stage prostate cancer include hormone therapy as well as non-hormone therapies like chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Often, hormone therapy is combined with one or more other therapies. Combining therapies can be more effective than using either therapy alone.

Hormone therapy

Hormone therapy is a systemic (whole-body) treatment that adds, blocks, or removes hormones. A hormone is a natural chemical made by a gland in the body. Its job is to activate cells or organs.

Male hormones are called androgens. The main androgen is testosterone. Most of the testosterone in the body is made by the testicles. Testosterone helps produce sperm, among other functions. But testosterone also helps prostate cancer grow. A type of hormone therapy called androgen deprivation therapy (ADT) can stop your body from making testosterone or block cancer cells from using testosterone. The key word in ADT is “deprivation”—this therapy “deprives” (starves) the cancer of its main fuel: androgens. This can shrink the tumor or slow tumor growth for a while.

You might hear the term “castration” used when describing prostate cancer or its treatment. This term describes a drastic reduction of testosterone. Castration can be done with hormone-lowering medication or by surgical removal of one or both testicles (orchiectomy). Though orchiectomy is a surgical procedure, it’s still considered hormone therapy because it removes the primary source of testosterone: the testicles. While drug hormone therapy can be reversed when the medication is stopped, orchiectomy is permanent and can’t be reversed.

Surgical removal of the testicles is much less common these days because systemic

What is ADT?

Androgen deprivation therapy (ADT) brings testosterone down to a very low level. ADT treatments include:

- **LHRH agonist** (goserelin, leuprolide, or triptorelin)
- **LHRH agonist + anti-androgen** (nilutamide, flutamide, or bicalutamide)
- **LHRH antagonist** (degarelix or relugolix)
- **Surgical castration**
hormone therapy is often just as effective at blocking testosterone.

Hormone therapies for prostate cancer include luteinizing hormone-releasing hormone (LHRH) agonists and LHRH antagonists, both of which cause the testicles to stop making testosterone. You may have heard of leuproide (Lupron), a commonly used LHRH agonist or degarelix (Firmagon), a commonly used LHRH antagonist. Most LHRH agonists and LHRH antagonists are injections. These may be given monthly, or 2, 3, or 4 times a year. The exception is relugolix (Orgovyx), an LHRH antagonist that comes as a tablet taken once a day. Anti-androgens, corticosteroids, and androgen synthesis inhibitors are also available as pills and taken 1 to 3 times a day, depending on the medication. See Guide 1.

**Newer hormone therapies**

Hormone therapy has been the main treatment for advanced prostate cancer for several decades. Longstanding hormone therapies (such as bicalutamide, flutamide, and nilutamide) are sometimes still used for treating prostate cancer.

---

**Guide 1**

**Hormone therapy drugs for prostate cancer**

<table>
<thead>
<tr>
<th><strong>Anti-androgens</strong> block receptors on prostate cancer cells from receiving testosterone.</th>
<th>apalutamide (Erleada), bicalutamide (Casodex), darolutamide (Nubeqa), enzalutamide (Xtandi), flutamide (Eulexin), nilutamide (Nilandron)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LHRH agonists</strong> prevent the release of luteinizing hormone-releasing hormone (LHRH), which causes the testicles to stop making testosterone.</td>
<td>goserelin (Zoladex), leuproide (Lupron Depot, Eligard), triptorelin (Trelstar)</td>
</tr>
<tr>
<td><strong>LHRH antagonists</strong> block or stop the pituitary gland (located in the brain) from making LHRH. This causes the testicles to stop making testosterone.</td>
<td>degarelix (Firmagon), relugolix (Orgovyx)</td>
</tr>
<tr>
<td><strong>Androgen synthesis inhibitors</strong> block androgen production.</td>
<td>abiraterone (Zytiga, Yonsa), ketoconazole (Nizoral)</td>
</tr>
<tr>
<td><strong>Corticosteroids (“steroids”)</strong> are synthetic hormones made in a lab that can stop the adrenal glands and other tissues from making testosterone.</td>
<td>dexamethasone, hydrocortisone, methylprednisolone, prednisone</td>
</tr>
</tbody>
</table>
However, newer hormone therapies are better at delaying the spread of cancer and extending life. These newer drugs include abiraterone, apalutamide, darolutamide, and enzalutamide. You may hear your treatment team refer to these as novel, advanced, or next-generation hormone therapies.

**Side effects of hormone therapy**

Hormone therapy can have significant side effects. These vary from person to person and from one type of hormone therapy to another. Many other factors affect your risk for side effects including your age, your health before treatment, how long or often you have treatment, and other things.

The good news is that your treatment team can offer supportive care to lessen or reverse many of these effects.

In general, the longer you’re on hormone therapy, the greater your risk for side effects. These can include tiredness (fatigue), hot flashes, mood changes, weight gain, changes in penis length and testicle size, tenderness and growth of your breasts, and loss of muscle mass.

Thinning and weakening of your bones (osteoporosis) and bone fractures can also happen. When you start ADT, you may have a test to measure your bone density. If your bone density is low, your care team can recommend medications you can take to strengthen your bones.

Hormone therapy also increases the risk for diabetes and cardiovascular disease. If you already have either of these conditions, hormone therapy can cause them to get worse. In Black patients, hormone therapy may increase the risk of death from heart issues.

Ask your doctor about monitoring your blood pressure and cholesterol levels. Also, let your primary care physician know you’re being treated with ADT.

LHRH agonists can cause a surge in testosterone for a few weeks before dropping to an undetectable level. This increase is called a testosterone flare. A testosterone flare can cause bone pain and urinary problems. But these symptoms will go away after the first few weeks of treatment. You might be given an anti-androgen medicine to prevent testosterone flare.

The sexual side effects of hormone therapy can be a significant cause of stress. Hormone therapy may reduce your desire for sex and cause erectile dysfunction.

Erectile dysfunction means having difficulty or being unable to have an erection of the penis. Erectile dysfunction medicines (such as Viagra and Cialis) aren't as effective for those on hormone therapy. These drugs don't restore the loss of sexual desire caused by lower androgen levels.

However, some treatments that may improve erectile function include injections of medication into the penis, vacuum constriction devices (“penis pump”), or surgical implants that produce an erection.

Your sex drive and your ability to have an erection may gradually return after stopping hormone therapy, though the process may take up to a year or more. Some patients never regain full ability to have an erection.
Erectile dysfunction is a leading cause of depression in patients with prostate cancer. Ask your care team about therapy or counseling if you’re having problems due to erectile dysfunction or symptoms of depression. Help is available.

Talk to your care team about how to manage the side effects of hormone therapy. They have ways to lessen or soothe most of these problems. Bones can be strengthened with medicine as well as with physical activity. Exercise and eating a healthy diet can also help with fatigue, mood, and weight gain.

Loss of sex drive, erectile dysfunction, and other sexual side effects usually go away after you stop hormone therapy. In the meantime, consider talking to your partner and/or a therapist to help you deal with any problems you’re having.

**Hormone therapy resistance**

Hormone therapy can be very effective at shrinking or slowing the growth of your prostate cancer. But for people with metastatic prostate cancer, hormone therapy can lose this effect over time, even when their testosterone is at a very low level.

Why? Because the cancer eventually learns how to survive without using much testosterone, which makes it unaffected by hormone therapy. The cancer can “resist” the hormone therapy. This is called hormone-resistant prostate cancer (also called castration-resistant prostate cancer).

Regular exercise can lessen the symptoms and side effects of hormone therapy, including:

- weight gain
- fatigue
- loss of bone and muscle mass

Physical activity can also improve your general health and make you feel better. Ask your care team to recommend an exercise program for you.

It’s important to know that prostate cancer that’s resistant to hormone therapy is still treatable. So most people with hormone-resistant prostate cancer stay on ADT to keep their testosterone at a low level.

Other hormone-reducing drugs are also still used. These hormone therapies are often combined with non-hormone treatments like chemotherapy, targeted therapy, or immunotherapy to help get better results.
Non-hormone therapy

Hormone therapy may be the first treatment recommended for advanced prostate cancer, but it’s not the only one. Other systemic treatments that don’t use hormones can also slow cancer growth, prevent cancer symptoms, and prolong life.

If you’re given non-hormone therapy, you’ll likely also stay on ADT to make sure your testosterone remains at the lowest possible level. See Guide 2.

Chemotherapy

Chemotherapy is a systemic drug treatment that damages rapidly dividing cells throughout the body. Cancer cells divide and multiply rapidly, which makes them a good target for chemotherapy.

But chemotherapy can harm healthy cells, too. That’s how it can cause side effects. Because chemotherapy can be a tough treatment to go through, it’s recommended only for those who are able to physically tolerate it. Despite the side effects, it can help people with metastatic prostate cancer live significantly longer.

Chemotherapy for prostate cancer is a liquid medicine given by intravenous infusion. This means that it’s slowly injected into a vein for up to an hour. It’s given every 3 weeks for a total of 6 to 10 times (cycles), along with a daily steroid.

Docetaxel

Docetaxel (Taxotere) is the chemotherapy medicine used most often to treat patients with advanced prostate cancer. Though docetaxel can’t cure prostate cancer, it can help people live longer as well as reduce their pain and other symptoms. Docetaxel is an option for some who are taking ADT for the first time. Docetaxel is also used to treat metastases after ADT fails to stop cancer growth.

Cabazitaxel

Cabazitaxel (Jevtana) is a chemotherapy option if docetaxel isn’t effective. Cabazitaxel can’t cure prostate cancer but it can help people live longer and improve pain and other symptoms.

Carboplatin and cisplatin

Carboplatin and cisplatin are chemotherapy drugs made from platinum. These are sometimes used for patients with very advanced or aggressive cancer. Usually, either carboplatin or cisplatin is combined with another chemotherapy medicine such as cabazitaxel or docetaxel.

Mitoxantrone

Mitoxantrone (Novantrone) is used to relieve pain and decrease the need for pain medications. It’s an option if you aren’t able to tolerate other therapies.

Immunotherapy

The immune system is the body’s natural defense against infection and disease. Immunotherapy is a type of systemic therapy that boosts the ability of your immune system to find and destroy cancer cells. Immunotherapy is usually given alone for treating prostate cancer. Immunotherapy drugs include sipuleucel-T and pembrolizumab.

Sipuleucel-T

Sipuleucel-T (Provenge) is intended for those with hormone-resistant metastatic prostate
cancer who have few or no symptoms. This drug is known as a “cancer vaccine.” First, immune cells are collected from your body and sent to a lab. The immune cells are then activated to identify and target prostate cancer cells. Lastly, the immune cells are injected back into your body where they attack cancer cells.

**Pembrolizumab**

Pembrolizumab (Keytruda) is a type of immunotherapy called an immune checkpoint inhibitor. For a small percentage of people whose prostate cancer is due to specific genetic mutations, pembrolizumab can restore the immune system’s ability to detect and destroy cancer cells.

### Guide 2
**Non-hormone systemic therapies for advanced prostate cancer**

<table>
<thead>
<tr>
<th>Type of therapy</th>
<th>Brand name</th>
<th>Generic name</th>
<th>Drug form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemotherapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taxotere</td>
<td></td>
<td>docetaxel</td>
<td></td>
</tr>
<tr>
<td>Jevtana</td>
<td></td>
<td>cabazitaxel</td>
<td></td>
</tr>
<tr>
<td>Paraplatin</td>
<td></td>
<td>carboplatin</td>
<td>infusion into a vein</td>
</tr>
<tr>
<td>Platinol</td>
<td></td>
<td>cisplatin</td>
<td></td>
</tr>
<tr>
<td>Novantrone</td>
<td></td>
<td>mitoxantrone</td>
<td></td>
</tr>
<tr>
<td><strong>Immunotherapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provenge</td>
<td></td>
<td>sipuleucel-T</td>
<td>infusion into a vein</td>
</tr>
<tr>
<td>Keytruda</td>
<td></td>
<td>pembrolizumab</td>
<td></td>
</tr>
<tr>
<td><strong>Biomarker-targeted therapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubraca</td>
<td></td>
<td>rucaparib</td>
<td>tablet</td>
</tr>
<tr>
<td>Lynparza</td>
<td></td>
<td>olaparib (plus abiraterone)</td>
<td></td>
</tr>
<tr>
<td>Akeega</td>
<td></td>
<td>niraparib/abiraterone</td>
<td></td>
</tr>
<tr>
<td>Talzenna</td>
<td></td>
<td>talazoparib (plus enzalutamide)</td>
<td>capsule</td>
</tr>
<tr>
<td><strong>Radiopharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pluvicto</td>
<td></td>
<td>lutetium-177</td>
<td>infusion into a vein</td>
</tr>
<tr>
<td>Xofigo</td>
<td></td>
<td>radium-223</td>
<td></td>
</tr>
<tr>
<td><strong>Bone-targeted therapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolia, Xgeva</td>
<td></td>
<td>denosumab</td>
<td>injection</td>
</tr>
<tr>
<td>Zometa</td>
<td></td>
<td>zoledronic acid</td>
<td></td>
</tr>
<tr>
<td>Fosamax</td>
<td></td>
<td>alendronate</td>
<td>tablet</td>
</tr>
</tbody>
</table>
**Biomarker-targeted therapy**

This treatment targets specific biomarkers that are found through molecular tumor testing. Biomarker-targeted therapies are useful only in patients whose prostate cancer is due to specific genetic mutations. This includes mutations in \textit{BRCA1}, \textit{BRCA2}, and other genes that repair damaged DNA. About 1 in 4 patients with metastatic hormone-resistant prostate cancer have this kind of genetic mutation.

Biomarker-targeted therapies (also known as PARP inhibitors) for advanced prostate cancer include rucaparib (Rubraca), olaparib (Lynparza), niraparib and abiraterone (Akeega), and talazoparib (Talzenna). Because genetic mutations differ between people, a treatment that helps one person may not help another.

**Radiopharmaceuticals**

A radiopharmaceutical is a medicine that contains a radioactive substance. This radioactive substance releases radiation to kill cancer cells. The radiation doesn't travel far from cancer cells so nearby healthy tissue remains mostly unharmed.

Radiopharmaceuticals are injected into a vein (intravenous injection). Because radiopharmaceuticals leave the body through the gut, common side effects are nausea, diarrhea, and vomiting.

Radiopharmaceutical drugs include lutetium-177 and radium-223:

**Lutetium-177**

Lutetium-177 (Pluvicto) is a targeted radiopharmaceutical that looks for a particular protein (prostate-specific membrane antigen, PSMA) on the surface of prostate cancer cells anywhere in the body. When the drug finds PSMA, it attaches itself to the cancer cells and implants a small amount of its radioactive substance in them. The cancer cells absorb the radiation from the drug and die.

Lutetium-177 is an intravenous infusion given once every 6 weeks for up to 6 doses. You'll need a PSMA-PET scan to find out if this treatment may work for you.

**Radium-223**

Radium-223 (Xofigo) is used to treat prostate cancer that has metastasized in bone but hasn't spread to other organs. Radium-223 collects in bones and gives off radiation that can kill prostate cancer cells there. It's an injection given once a month for 6 months. You'll need to have blood tests before each dose. A bone-targeting therapy, either denosumab or zoledronic acid, is often given with radium-223.

Radium-223 is also used to reduce pain from bone metastases.

**Radiation therapy**

Radiation therapy uses high-energy rays, like x-rays or gamma rays, to kill cancer cells and shrink tumors. Radiation therapy is given in regular doses over a certain period of time.

External beam radiation therapy (EBRT) is the type of radiation used for prostate cancer. EBRT uses a machine that aims radiation precisely at cancer inside the body. The
radiation beam focuses directly on the cancer while trying to avoid healthy tissue. This technique delivers higher doses of radiation more safely.

For metastatic prostate cancer, radiation therapy is mainly used for treatment of prostate cancer that returns after initial treatment (recurrence). Radiation therapy is also used as palliative treatment to relieve the pain of bone metastases.

Radiation therapy (EBRT) is more commonly used along with hormone therapy as the initial treatment for patients who have early-stage or regional prostate cancer. EBRT treats the prostate as well as cancerous lymph nodes, while hormone therapy lowers testosterone to a minimal level to prevent the cancer from getting worse.

Some of the possible side effects of radiation therapy are urinary and bowel problems, erectile dysfunction, and fatigue.

Clinical trials

Therapy may also be given as part of a clinical trial.

A clinical trial is a type of medical research study. Clinical trials are a key way to assess new treatment approaches.

After being developed and tested in a laboratory, potential new ways of fighting cancer need to be studied in people. If found to be safe and effective in a clinical trial, a drug, device, or treatment approach may be approved by the FDA.

Everyone with cancer should carefully consider all the treatment options available for their cancer type, including standard treatments and clinical trials. Talk to your doctor about whether a clinical trial may make sense for you.

Black males have a higher risk of developing and dying from prostate cancer. But many may not know about clinical trial opportunities. As a result, not as much is known about whether new treatments can work for Black males with prostate cancer.

Everyone with cancer can ask for and should be given information about clinical trials. Knowing all the options means not missing out on clinical trial opportunities for promising new treatments.
Prostate cancer treatments  » Clinical trials

Who can enroll?

Every clinical trial has rules for joining, called eligibility criteria. The rules may be about age, cancer type and stage, treatment history, or general health. These requirements ensure that participants are alike in certain ways in order to compare how their disease responds to a specific treatment.

Informed consent

Clinical trials are managed by a group of experts called a research team. The research team will review the study with you in detail, including its purpose and the risks and benefits of joining.

All of this information is also provided in an informed consent form. This is an agreement that confirms you’ve been fully told about your part in the trial. Read the form carefully and ask questions before signing it. And discuss it with family, friends, or others you trust.

Keep in mind that clinical trials are voluntary and you can seek treatment outside of the clinical trial at any time.

Start the conversation

Don’t wait for your doctor to bring up clinical trials. Start the conversation and learn about all your treatment options. Ask if a clinical trial is available for your situation. If you find a study that you may be eligible for, ask your treatment team if you meet the requirements.

If you have already started standard treatment, you may not be eligible for certain clinical trials. Try not to be discouraged if you cannot join. New clinical trials are always becoming available.

Finding a clinical trial

In the United States

NCCN Cancer Centers
NCCN.org/cancercenters

The National Cancer Institute (NCI)
cancer.gov/about-cancer/treatment/clinical-trials/search

Worldwide

The U.S. National Library of Medicine (NLM)
clinicaltrials.gov

Need help finding a clinical trial?

NCI’s Cancer Information Service (CIS)
1.800.4.CANCER (1.800.422.6237)
cancer.gov/contact

Frequently asked questions

There are many myths and misconceptions surrounding clinical trials. The possible benefits and risks are not well understood by many with cancer.
Without clinical trials, our treatment wouldn’t change. It would always remain the same. Some people refer to clinical trials as receiving tomorrow’s best treatment today.”

Will I get a placebo?
Placebos (inactive versions of real medicines) are almost never used alone in cancer clinical trials. It’s common to receive either a placebo with a standard treatment or a new drug with a standard treatment. You’ll be informed if a placebo is part of a clinical trial before you enroll.

Are clinical trials free?
There’s no fee to enroll in a clinical trial. The study sponsor pays for research-related costs, including the study drug. You may, however, have costs indirectly related to the trial, such as the cost of transportation or childcare due to extra appointments.

Depending on the trial, you may continue to receive standard cancer care. The standard therapy is billed to—and often covered by—insurance. You’re responsible for copays and any costs for this care that aren’t covered by your insurance.

Supportive care
Supportive care (also called palliative care) treats cancer symptoms, the side effects of cancer treatment, and other related health issues. All patients with advanced cancer should be offered supportive care.

Supportive care is important at any stage of cancer, not just at the end of life. In fact, people who start supportive care when they begin treatment tend to have better quality of life and potentially improved outcomes.

Bone-targeted therapy
Supportive care may be especially useful for patients with bone metastases. Prostate cancer that metastasizes to bones can cause severe pain, fractures (breaks) in bones, bone loss (osteoporosis), and squeezing (compression) of the spinal cord.

Also, some treatments for prostate cancer, like hormone therapy, can cause osteoporosis and increase your risk of fractures.

If you’re at risk for osteoporosis, you may have a bone mineral density test. This is a special x-ray scan that measures how much calcium and other minerals are in your bones. Bone mineral density tests look for osteoporosis and help predict your risk for bone fractures.

You should have a follow-up bone mineral density test after 1 year of hormone therapy. You might also have blood tests to monitor kidney function and calcium levels.
Shared decision-making

Some people with cancer want their doctors and treatment team to just tell them which treatment to have. Doctors, nurses, and other providers are the experts, right? While it's true that your treatment team has lots of experience and knowledge, you're also an expert—you're the expert on you.

It’s a good idea for your team to share the responsibility of your treatment with you. And it’s a good idea for you to fully participate in making decisions about your care.

Here’s what your treatment team should share with you:

• An explanation of the likely benefits and potential harms of each treatment option.
• The likelihood of cure, recurrence, progression, and possible mortality with each treatment option.
• The side effects of each treatment option along with their impact on quality of life, including sexual, urinary, and bowel function.

And here’s what you should share with your treatment team:

• Your preferences and feelings about treatment, side effects, risks, and quality of life. These should be key parts of your treatment plan.
• If the provider who’s leading your treatment team doesn’t have a talk with you about shared decision-making, feel free to speak up and ask about it.
Medicines that target bones can help to relieve bone pain and reduce the risk of bone problems. Some medicines work by slowing or stopping bone breakdown, while others help increase bone thickness. Drugs include Prolia (denosumab), Xgeva (denosumab), Zometa (zoledronic acid), and Fosamax (alendronate).

For more information about supportive care, see Chapter 6.

Key points

- Testosterone helps prostate cancer grow.
- Hormone therapy treats prostate cancer by stopping testosterone from being made or by blocking cancer cells from using testosterone.
- Hormone therapy can eventually lose its effectiveness against prostate cancer. This becomes hormone-resistant prostate cancer.
- Hormone therapy is often combined with one or more other therapies, which can be more effective together at slowing or shrinking advanced prostate cancer.
- Other treatments used with hormone therapy for advanced prostate cancer include chemotherapy, immunotherapy, target therapy, radiopharmaceuticals, and radiation therapy.
- Hormone therapy can cause a number of possible side effects. But treatment and therapy are available.
- Supportive care relieves the symptoms caused by cancer and the side effects caused by its treatment. Everyone with advanced-stage prostate cancer should be offered supportive care.

What’s next?

This chapter described the available treatment options for advanced-stage prostate cancer, which includes both regional prostate cancer and metastatic prostate cancer.

If you’ve been diagnosed with regional prostate cancer, turn to the next chapter to read about the typical therapies included in your treatment plan.

If you’ve been diagnosed with metastatic prostate cancer, go to Chapter 5 to read about the common (and uncommon) treatment options for this advanced-stage cancer.
Regional prostate cancer treatment options

38 About regional prostate cancer
38 Treatment
42 Follow-up after treatment
42 Treatment for persistence or recurrence
44 What’s next?
44 Key points
Regional prostate cancer has grown outside the prostate gland to nearby areas like lymph nodes, but not any farther. It usually requires both local and systemic (whole-body) treatment.

About regional prostate cancer

Regional prostate cancer is cancer that has spread from the prostate gland to neighboring tissue, such as nearby lymph nodes, the bladder, or the rectum. But it hasn’t spread any farther. (To read about prostate cancer that has spread to distant lymph nodes, bones, or organs, turn to Chapter 5.) Regional prostate cancer is also sometimes called locally advanced prostate cancer.

Treatment

The key concern about prostate cancer that spreads just outside the prostate is that it could continue to spread farther (metastasize) to other areas of the body. As a result, treatment for regional prostate cancer is more aggressive than treatment for early-stage prostate cancer.

Treatment takes aim at cancer in the prostate itself as well as cancer outside the prostate. So it often includes both local therapy (radiation therapy or prostate surgery) and systemic therapy (hormone therapy).

Treatment options are also based on life expectancy and symptoms. The longer the life expectancy and the more symptoms, the more aggressive the treatment. See Guide 3.

Life expectancy

Life expectancy is the average lifespan of a person. It’s measured in years. An estimate of your life expectancy may be a key factor in deciding which tests and treatments you’ll need.

It’s important to know that life expectancy—when used for cancer care—is an estimate based on large numbers of people. That means life expectancy can be applied to a certain population or age range, but it’s not as easy to make a precise estimate of the lifespan of an individual person.

Life expectancy: More than 5 years or you have symptoms

If your life expectancy is more than 5 years or you have symptoms, treatment usually includes:

Radiation therapy

External beam radiation therapy (EBRT along with long-term hormone therapy plus abiraterone (Zytiga) is the preferred initial treatment for patients who have regional prostate cancer and a longer life expectancy or symptoms. Preferred treatments are ones that have the most scientific evidence that they work well.

EBRT treats the prostate as well as cancerous lymph nodes, while long-term hormone therapy lowers testosterone to a minimal level to prevent the cancer from getting worse. Long-
Long-term hormone therapy is given before, during, and after EBRT for 2 to 3 years.

**Hormone therapy**

Long-term hormone therapy consists of androgen deprivation therapy (ADT) plus abiraterone, an androgen inhibitor. If you’re taking abiraterone, you’ll also need to take a steroid to reduce abiraterone’s side effects.

Another option for initial treatment is radiation therapy plus long-term (2 to 3 years) ADT without the addition of abiraterone. This may be an option for those who can’t take abiraterone due to other health conditions.

ADT on its own is an option for patients with regional prostate cancer who have other significant or life-threatening health problems. Abiraterone can be added to ADT, which may help patients live longer although it may also come with more side effects.

**Prostate surgery**

Prostatectomy means removing the prostate gland through surgery. A radical prostatectomy removes not only the entire prostate but also the surrounding tissue and seminal vesicles. A pelvic lymph node dissection (PLND) is an operation to remove the nearby lymph nodes.

A radical prostatectomy with PLND is a treatment option only in certain cases of regional prostate cancer. It’s used when:

- The tumor is found only in the prostate.
- The tumor can be removed completely with surgery.

---

**Guide 3**  
**Regional risk group: Initial therapy options**

<table>
<thead>
<tr>
<th>Life expectancy</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than 5 years or you have symptoms</td>
<td>EBRT with ADT + abiraterone + steroid (preferred)</td>
</tr>
<tr>
<td></td>
<td>EBRT with ADT</td>
</tr>
<tr>
<td></td>
<td>ADT with or without abiraterone</td>
</tr>
<tr>
<td></td>
<td>Radical prostatectomy and dissection of pelvic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>Additional treatment:</td>
</tr>
<tr>
<td></td>
<td>• Monitoring (preferred)</td>
</tr>
<tr>
<td></td>
<td>• EBRT with or without ADT</td>
</tr>
<tr>
<td></td>
<td>• ADT with or without EBRT</td>
</tr>
<tr>
<td>5 years or less and you have no symptoms</td>
<td>Observation</td>
</tr>
<tr>
<td></td>
<td>ADT</td>
</tr>
</tbody>
</table>
You have a life expectancy of 10 or more years.

You have no other serious health conditions.

A radical prostatectomy is complex and requires a great deal of skill. Surgeons who are experienced in this type of surgery often have better results.

Even so, sometimes cavernous nerve bundles are damaged or removed during surgery. The cavernous nerves control the ability to have erections. These nerves run alongside the prostate. Surgeons do their best to avoid these nerves when performing a prostatectomy, but damage to the nerves during surgery is sometimes unavoidable. This damage can cause side effects.

Possible side effects of radical prostatectomy can include urinary incontinence and erectile dysfunction.

Urinary incontinence (being unable to hold your urine) is usually temporary. Most patients gradually recover control of their bladder after a few months or so. Doing exercises to strengthen the pelvic floor can help. If incontinence continues to be a problem, another surgical procedure can be done to improve it.

Erectile dysfunction may slowly improve over several months to 2 years after the surgery. However, you may never regain the same erectile function you once had. Treatment options include pills (like Viagra and Cialis), injections of medication into the penis, vacuum constriction devices ("penis pump"), and surgical implants that produce an erection.

Erectile dysfunction is a leading cause of depression in patients with prostate cancer. Ask your care team about therapy or counseling if you're having any problems due to erectile dysfunction or any symptoms of depression. Help is available.

About 1 in 8 people who are diagnosed with prostate cancer have prostate cancer that is regional.
Additional therapy after prostate surgery
Because the surgeon is able to see inside your body during prostate surgery, it often reveals more details about your disease. It could show that the cancer has spread to nearby lymph nodes. Or there may be other signs of cancer after the prostate is removed. In either case, you might have additional treatment at some point after the surgery.

If there are signs of remaining cancer but no metastasis in lymph nodes, additional treatment involves EBRT with or without added hormone therapy.

But additional treatment, like any treatment, comes with some risk of side effects. So instead of active therapy, your care team may suggest that you delay additional treatment but have regular testing until signs or symptoms (such as a rising PSA level) begin to occur. This is called monitoring.

If prostate surgery shows that the cancer has spread to the lymph nodes, monitoring may still be an option. If active therapy is recommended instead, the treatment involves ADT with or without EBRT.

I had a radical prostatectomy. Because my prostate cancer was very close to one nerve bundle, I chose to have it removed also. I wasn’t troubled by this because I learned that there are other ways of getting erections. I wanted to live to see my grandchildren grow up, and now they have!”

Life expectancy: 5 years or less and you have no symptoms
Treatment is less aggressive for people with regional prostate cancer whose life expectancy is 5 years or less and who have no symptoms:

Observation
Observation is an option for patients with a life expectancy of 5 years or less. It’s for those with other serious health problems whose prostate cancer isn’t causing any symptoms. Observation involves occasional PSA tests and watching for symptoms, which can be treated with pain-relieving (palliative) therapy.

ADT
ADT on its own is an option for patients with regional disease, no symptoms, and a life expectancy of 5 years or less. It’s used to slow cancer and delay or reduce symptoms. ADT may include an LHRH agonist, an LHRH antagonist, or surgical removal of the testicles.
Follow-up after treatment

After initial treatment, you’ll have follow-up tests to find out how well your therapy worked. Periodic prostate-specific antigen (PSA) tests and occasional imaging scans can indicate whether the cancer is under control.

PSA is very low or undetectable

If your PSA is very low after radiation therapy or undetectable after prostate surgery, you’ll be monitored for cancer recurrence.

Monitoring involves PSA testing every 6 to 12 months for several years. Patients with a high risk of recurrence may have PSA testing more often, such as every 3 months. You’ll continue to be monitored on an ongoing basis or until signs or symptoms occur.

PSA is elevated or rising

If your PSA doesn’t fall to an undetectable level after prostate surgery, you may still have cancer (persistence). Or, if your PSA drops after initial treatment but then later rises again, it probably means the cancer has come back (recurrence). In either case, further treatment is available.

Treatment for persistence or recurrence

If you have PSA persistence or recurrence after your initial therapy, your life expectancy will guide what treatment you may have next.

More than 5 years

Before deciding on any treatment, you’ll need some more tests to find out how aggressive the cancer may be. Tests include PSA doubling time; imaging with CT, MRI, or whole-body PET scan; and possibly a biopsy. Results of these tests will indicate your next treatment.

In addition, treatment for cancer persistence or recurrence is based on whether your initial treatment for regional prostate cancer was radiation therapy or prostate surgery. See Guide 4.

5 years or less

If your life expectancy is 5 years or less, observation may be a better option than undergoing treatment. Observation involves checking up on your prostate cancer and watching for symptoms.

If symptoms develop, treatment is often focused on easing or stopping them instead of trying to cure the cancer. This allows patients to maintain a good quality of life without the burden of unnecessary treatment.
## Guide 4

### Treatment for PSA persistence or recurrence

<table>
<thead>
<tr>
<th>Initial therapy</th>
<th>Imaging results</th>
<th>Treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Radical prostatectomy</strong></td>
<td>No other signs of cancer</td>
<td>• Radiation therapy with or without hormone therapy (preferred)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring</td>
</tr>
<tr>
<td></td>
<td>Cancer in pelvic lymph nodes</td>
<td>• Radiation therapy and hormone therapy, with or without abiraterone</td>
</tr>
<tr>
<td></td>
<td>Cancer has spread to another area of the body</td>
<td>• Advanced treatment required</td>
</tr>
<tr>
<td></td>
<td>(metastasized)</td>
<td></td>
</tr>
<tr>
<td><strong>Radiation therapy</strong></td>
<td>No other signs of cancer or Cancer only in the prostate</td>
<td>• Biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hormone therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Radical prostatectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cryotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• High-intensity focused ultrasound</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• More radiation therapy</td>
</tr>
<tr>
<td></td>
<td>Cancer in pelvic lymph nodes</td>
<td>• Biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hormone therapy with or without abiraterone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Radiation therapy of pelvic lymph nodes with or without hormone therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dissection of pelvic lymph nodes with or without hormone therapy</td>
</tr>
<tr>
<td></td>
<td>Cancer has spread to another area of the body</td>
<td>• Advanced treatment required</td>
</tr>
<tr>
<td></td>
<td>(metastasized)</td>
<td></td>
</tr>
</tbody>
</table>
What’s next?

After you’ve been treated for regional prostate cancer, and perhaps PSA persistence or PSA recurrence, you’ll continue to have tests and visits to treat your existing cancer or to watch out for cancer to return.

Surveillance is a key part of your follow-up plan. Be sure to continue to go to follow-up visits, have your PSA tested regularly, and stay in touch with your treatment team.

If the cancer comes back again but doesn’t spread beyond the pelvis, you can continue to have treatment for persistence/recurrence.

If the cancer comes back again but spreads to another area of the body, you’ll need more advanced treatment. See the next chapter for treatment options for metastatic prostate cancer.

Key points

- Regional prostate cancer has spread from the prostate gland to neighboring tissue, but no farther.
- The main concern about regional prostate cancer is that it could continue to spread to other areas of the body.
- Treatment for regional prostate cancer often includes both local therapy and systemic therapy.
- The preferred initial treatment for regional prostate cancer in people with a longer life expectancy or symptoms is external beam radiation therapy (EBRT), long-term androgen deprivation therapy (ADT), and abiraterone.
- Treatment is less aggressive for people with regional prostate cancer whose life expectancy is 5 years or less and who have no symptoms.
- Prostate-specific antigen (PSA) persistence is when your PSA doesn’t fall to an undetectable level. This indicates the cancer hasn’t gone away.
- PSA recurrence is when your PSA level drops after initial treatment but rises again. This indicates the cancer has come back.
5

Metastatic prostate cancer treatment options

46 About metastatic prostate cancer
46 Main treatment
47 Hormone-sensitive treatment
49 Hormone-resistant treatment
55 What’s next?
55 Key points
About metastatic prostate cancer

Metastatic prostate cancer is cancer that has spread (metastasized) outside the prostate and beyond the pelvis to other areas of the body.

Areas where prostate cancer tends to spread are:

- **Lymph nodes** farther away from the prostate
- **Bones** in the spine, pelvis, or ribs
- **Organs** such as the liver, lungs, brain, or others

You may have metastatic cancer when you’re first diagnosed. Or your cancer may become metastatic after you’ve already had treatment for early-stage or regional prostate cancer.

Metastatic prostate cancer can be difficult to treat. However, a variety of therapies are available to target the cancer, stop or slow its progress, reduce symptoms, and prolong life.

Main treatment

The main treatment for metastatic prostate cancer is hormone therapy, specifically androgen deprivation therapy (ADT).

The aim of ADT is to reduce androgens (mostly testosterone) to a point where they don’t provide fuel for the cancer. This low point is called castration level, which is when there’s nearly zero testosterone in the bloodstream.

Patients whose metastatic prostate cancer is newly diagnosed will begin ADT to get their testosterone down to castration level. Patients with metastatic prostate cancer who are already being treated with ADT will continue the treatment to keep testosterone at a minimal level.

ADT comes in a few forms. These include drugs (an LHRH agonist with or without an anti-androgen, or an LHRH antagonist) or sometimes surgery (removal of the testicles).

Although ADT is the main therapy for advanced prostate cancer, it’s not usually given on its own any more. Adding one or two additional therapies to ADT may help you live longer and with fewer symptoms.

Additional therapies include second hormone therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals. You may hear this called doublet therapy (ADT + another therapy) or triplet therapy (ADT + two additional therapies).

Which additional therapy you’ll have depends on a number of considerations. The first consideration is whether ADT is still effective.
for you. To put it into medical terms, is your cancer hormone **resistant** or is it hormone **sensitive**?

**Hormone-resistant prostate cancer** (also called castration-resistant prostate cancer) is cancer that learns how to grow without using testosterone as its fuel. As a result, hormone therapy is no longer as effective against it—most of the cancer becomes “resistant” to ADT.

If you’ve had ADT but it’s no longer working well, go to page 49 to read about treatment options for hormone-resistant metastatic prostate cancer.

**Hormone-sensitive prostate cancer** (also called castration-sensitive prostate cancer) is not currently being treated with ADT or has never been treated with ADT. (This **doesn’t** include ADT given as short-term additional therapy, such as hormone therapy given during radiation therapy.) As a result, this cancer is “sensitive” to hormone therapy.

That is, hormone therapy can still treat it. You may also hear it called by its former name, castration-naïve prostate cancer, which means that hormone therapy is a new (“naïve”) treatment for the cancer.

If this describes your cancer, read the following section about treatment options for hormone-sensitive prostate cancer.

**Hormone-sensitive treatment**

As its name implies, hormone-sensitive metastatic prostate cancer is treated mainly with hormone therapy. ADT is considered the first hormone therapy. But a second hormone-reducing therapy is commonly added to ADT for treating advanced prostate cancer. It can prevent your cancer from growing and spreading farther. **See Guide 5.**

“When you are deciding on your treatment options, remember that even though some decisions need to be made fast, don’t rush. Think through your options and get second, or even third opinions. Have people you can trust to talk through your options so you feel comfortable in your decisions.”
**Preferred treatments**

Preferred treatments are ones that have the most scientific evidence that they work well. Preferred treatment options for hormone-sensitive prostate cancer include ADT plus a second hormone-reducing medicine. Medical research has shown that patients on ADT plus another hormone-reducing medicine tend to live longer than those on ADT alone. The preferred second hormone-reducing medicines are abiraterone, apalutamide, and enzalutamide. Your care team will talk to you about which medicine might work best for you.

If you’re prescribed abiraterone, you’ll also be given a steroid medication. The steroid helps reduce the side effects of abiraterone.

Other preferred treatments for hormone-sensitive metastatic prostate cancer are triplet therapy options: ADT plus a chemotherapy medicine (docetaxel) plus a hormone-reducing medicine (either abiraterone or darolutamide).

This adds up to a lot of medicine. So triplet therapy is only recommended for people who have high-volume prostate cancer who also can physically tolerate chemotherapy while on hormone therapy, plus other treatment. High-volume prostate cancer means having multiple metastases in bones and/or at least one metastasis in an internal organ. (Prostate cancer that has spread to an internal organ is called a visceral metastasis.)

**Other treatments**

Low-volume prostate cancer means having zero to a few metastases in bones and/or some metastases in distant lymph nodes, with no metastases in internal organs.

---

**Guide 5**

**Treatment options for hormone-sensitive prostate cancer**

<table>
<thead>
<tr>
<th>Preferred options</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADT + abiraterone (Zytiga) + steroid</td>
<td></td>
</tr>
<tr>
<td>ADT + apalutamide (Erleada)</td>
<td></td>
</tr>
<tr>
<td>ADT + enzalutamide (Xtandi)</td>
<td></td>
</tr>
<tr>
<td>ADT + chemotherapy (docetaxel) + abiraterone (Zytiga) + steroid</td>
<td>darolutamide (Nubeqa)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other options</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADT + radiation therapy (EBRT)</td>
<td></td>
</tr>
<tr>
<td>ADT + radiation therapy (EBRT) + abiraterone</td>
<td></td>
</tr>
</tbody>
</table>
For patients with low-volume hormone-sensitive prostate cancer, ADT plus external beam radiation therapy (EBRT) to the metastases is recommended to help stop the cancer from spreading farther. In some cases, abiraterone (or docetaxel chemotherapy) is given in addition to ADT and EBRT for a stronger effect.

ADT used by itself is usually not recommended for hormone-sensitive metastatic prostate cancer, except for patients who aren’t able to handle side effects or take other medicines.

**Follow-up visits**

After treatment, you’ll have follow-up tests on a regular basis to see how well the treatment is working and to check for any signs or symptoms that the cancer has returned.

If follow-up tests find that treatment isn’t working and your hormone-sensitive prostate cancer is growing or spreading, then you may have developed hormone-resistant prostate cancer. This is discussed next.

**Hormone-resistant treatment**

Hormone-resistant metastatic prostate cancer is cancer that keeps growing even when testosterone is at a very low level. How? Some cancer cells learn to survive without the usual supply of testosterone. Also, the cancer may get some androgens from the adrenal glands, which make a small amount of testosterone. Even the tumor itself can create androgens that help cancer cells grow. As these cells multiply, ADT gradually loses its effectiveness against the cancer.

**ADT**

To treat hormone-resistant metastatic prostate cancer, your testosterone needs to remain at castration level. So it’s still important to stay on ADT. Your care team may keep you on your same ADT treatment or might ask you to switch to a different medicine.

Besides ADT, your care team will recommend additional treatment. See *Guide 6* and *Guide 7*. Which treatment you’ll receive will depend on a few factors. These include:

- Your previous treatment (if any)
- Location of the metastasis in your body
- Amount of metastatic disease
- Symptoms
- Potential side effects
- Your preferences

In addition to ADT, treatments for hormone-resistant metastatic prostate cancer include second hormone therapy, chemotherapy,
immunotherapy, biomarker-targeted therapies, and radiopharmaceuticals—or a combination of these treatments.

If you were first diagnosed with early prostate cancer or hormone-sensitive prostate cancer, then you may have already had ADT and chemotherapy or next-generation hormone therapy. Having had either of these therapies will affect which treatment you’ll have next.

Second hormone therapy
ADT is the first hormone therapy used for treating metastatic prostate cancer. If prostate cancer becomes hormone resistant, then a second hormone therapy is commonly added. A second hormone therapy may be able to slow down your cancer or keep it from spreading farther. The preferred second therapy options include newer (next-generation) hormone therapies:

- Abiraterone (Zytiga)
- Enzalutamide (Xtandi)

Other second hormone therapy
If the preferred second hormone therapies don’t slow down your cancer, there are other hormone-reducing options:

- Adding one of the early-generation anti-androgens (nilutamide, flutamide, or bicalutamide) may be effective if newer hormone therapies aren’t an option due to cost or availability.
- Stopping an anti-androgen may also be effective. Sometimes stopping the drug has the opposite effect of lowering PSA levels in some patients.

- A corticosteroid (hydrocortisone, prednisone, or dexamethasone) can be a hormone-reducing therapy itself when used in addition to ADT.
- Ketoconazole (Nizoral) is a pill that’s occasionally prescribed when second hormone therapy or chemotherapy can’t be used or isn’t available. It’s taken with a steroid (hydrocortisone) to reduce side effects such as nausea and vomiting.

Chemotherapy
ADT plus chemotherapy can be the first treatment for metastatic prostate cancer or it can be given later if other treatments haven’t worked well. Chemotherapy can be given as a single drug (such as docetaxel) or as a pair (cabazitaxel and carboplatin) if the cancer is more aggressive.

Docetaxel is the preferred chemotherapy. Other chemotherapy drugs may be used in certain cases. These include cabazitaxel, cisplatin, carboplatin, and mitoxantrone.

You can also take a steroid (prednisone or dexamethasone) to reduce the side effects of chemotherapy.
**Immunotherapy**

Immunotherapy drugs boost the body’s own immune system to fight cancer. However, immunotherapy for prostate cancer is used only for certain patients. Immunotherapy drugs include:

- Sipuleucel-T (Provenge) can be used for patients whose hormone-resistant metastatic prostate cancer is causing few or no symptoms. Such patients usually have less cancer and a stronger immune system, which allows this immunotherapy to be more effective. Sipuleucel-T is not recommended for those whose prostate cancer has spread to internal organs.

- Pembrolizumab (Keytruda) is recommended only for patients whose hormone-resistant metastatic prostate cancer has grown or spread despite having chemotherapy and second hormone therapy. Patients’ test results will also show specific genetic changes (defects in DNA called mismatch repair deficiency and high microsatellite instability).

**Targeted therapy**

Biomarker-targeted therapies are useful only in patients whose hormone-resistant metastatic prostate cancer is linked with specific genetic mutations. These drugs are called PARP inhibitors because they target PARP, which is a
### Guide 7

#### Treatment options for specific cases of hormone-resistant prostate cancer

<table>
<thead>
<tr>
<th>Specific case</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If you have few or no symptoms and prostate cancer hasn’t spread to other</td>
<td>ADT + sipuleucel-T (Provenge)</td>
</tr>
<tr>
<td>internal organs</td>
<td></td>
</tr>
<tr>
<td>If you have a <em>BRCA</em> mutation and haven’t been treated for hormone-resistant</td>
<td>ADT + niraparib/abiraterone (Akeega) +</td>
</tr>
<tr>
<td>prostate cancer</td>
<td>prednisone</td>
</tr>
<tr>
<td>If you have a <em>BRCA</em> mutation and were already treated with hormone therapy</td>
<td>ADT + rucaparib (Rubraca)</td>
</tr>
<tr>
<td>and chemotherapy</td>
<td></td>
</tr>
<tr>
<td>If you have a DNA-repair gene mutation (<em>BRCA</em> or other) and haven’t</td>
<td>ADT + talazoparib (Talzenna) +</td>
</tr>
<tr>
<td>received treatment for hormone-resistant prostate cancer</td>
<td>enzalutamide (Xtandi)</td>
</tr>
<tr>
<td>If you have a DNA-repair gene mutation (<em>BRCA</em> or other) and were already</td>
<td>ADT + olaparib (Lynparza)</td>
</tr>
<tr>
<td>treated with hormone therapy</td>
<td></td>
</tr>
<tr>
<td>If you have aggressive metastatic prostate cancer or more than one genetic</td>
<td>ADT + cabazitaxel (Jevtana) + steroid, with</td>
</tr>
<tr>
<td>mutation, and docetaxel isn’t a good option</td>
<td>or without carboplatin</td>
</tr>
<tr>
<td>If you need pain relief but can’t take other therapies</td>
<td>ADT + mitoxantrone (Novantrone) + prednisone</td>
</tr>
<tr>
<td>If you have bone metastases that are causing symptoms but have no other</td>
<td>ADT + radium-223 (Xofigo)</td>
</tr>
<tr>
<td>metastases</td>
<td></td>
</tr>
<tr>
<td>If your prostate cancer produces PSMA and you already received hormone</td>
<td>ADT + lutetium-177 (Pluvicto)</td>
</tr>
<tr>
<td>therapy and chemotherapy</td>
<td></td>
</tr>
<tr>
<td>If you have certain genetic mutations (high microsatellite instability or</td>
<td>ADT + pembrolizumab (Keytruda)</td>
</tr>
<tr>
<td>high tumor mutational burden) and were already treated with hormone therapy</td>
<td></td>
</tr>
<tr>
<td>and chemotherapy</td>
<td></td>
</tr>
</tbody>
</table>
protein that cells use to repair damaged DNA. Biomarker-targeted therapies include:

- Olaparib (Lynparza) plus abiraterone and a steroid can be used for patients with a BRCA mutation before having second hormone therapy or chemotherapy. Olaparib may also be used for patients whose metastatic cancer has grown or spread after second hormone therapy (abiraterone or enzalutamide) and who have a mutation in a BRCA gene or other gene that repairs DNA.
- Rucaparib (Rubraca) can be used for patients with a BRCA mutation whose cancer has already been treated with both second hormone therapy and chemotherapy (docetaxel or cabazitaxel).
- Niraparib and abiraterone (Akeega) plus prednisone is a new targeted therapy for patients with a BRCA mutation. Patients should also be on an LHRH agonist, LHRH antagonist, or have had orchiectomy (surgical removal of the testicles).
- Talazoparib (Talzenna), taken with enzalutamide (Xtandi), is another new targeted therapy for patients with a mutation in a BRCA or other DNA-repair gene.

### Radiopharmaceuticals

If your initial or other treatments haven’t worked well, your care team may suggest a radiopharmaceutical drug.

- Lutetium-177 (Pluvicto) isn’t used until after both a second hormone therapy and chemotherapy (docetaxel or cabazitaxel) have been given. First, you’ll have PSMA-PET imaging to confirm the treatment could work.
- Radium-223 (Xofigo) can be used if prostate cancer has spread mainly to bones but not to internal organs. It should only be used in combination with ADT, not with second hormone therapy or chemotherapy.

### Clinical trial

Participating in a clinical trial is often an option. You can try to join a clinical trial at any time. You don’t need to wait until you feel like you have no other options.

### Supportive care

Supportive care for patients with bone metastases includes:

- **Bone-targeted therapy** – Denosumab or zoledronic acid to help prevent fractures
- **Palliative radiation therapy** – Direct radiation to painful bone tumors or tumors that interfere with bodily functions
- **Other treatments** – Calcium or vitamin D supplements to help prevent fractures
Follow-up visits
After treatment, you'll have follow-up tests on a regular basis to see how well the treatment is working and if there are any side effects from treatment. Tests include:

- Physical exam with PSA test every 3 to 6 months or more often
- Imaging if cancer symptoms occur
- Imaging as needed to look for cancer growth or spread

No growth or spread
If the cancer doesn’t grow or spread, your current treatment may be keeping your cancer in check. Your provider will continue to give you tests. If your situation remains stable, you'll stay on your current treatment unless changes or symptoms begin to occur.

Growth or spread
If your cancer grows or spreads, your treatment team may suggest you retry a therapy you’ve had before or try a new and different therapy. Many patients with advanced prostate cancer eventually receive two, three, or more different therapies in the course of their treatment.

If possible, consider all the treatment options. Talk with your team about what you want from treatment. You may ask for a second opinion before you start another therapy. You can explore any clinical trials that are available. And you always have the option to stop systemic therapy.

You'll continue to be offered supportive care.
What’s next?

Surveillance is a key part of your follow-up plan. Be sure to continue to go to follow-up visits and stay in touch with your treatment team.

It’s common to feel frustration, anger, regret, despair, and uncertainty—even all at the same time. Know that you can have prostate cancer and still find happiness after diagnosis and treatment. Try to enjoy life as much as possible. Talk with family or friends. Join a support group to learn how other patients are dealing with their cancer. Or talk to your doctor or another member of your care team. They can point you to professionals who can help you deal with these feelings and guide you toward your next steps.

Key points

- Metastatic prostate cancer has spread outside the prostate and beyond the pelvis to other areas of the body, such as distant lymph nodes, bones, or organs.
- The first treatment for advanced metastatic prostate cancer is usually ADT. Adding another therapy or two to ADT may help you live longer and with fewer symptoms.
- Hormone-sensitive prostate cancer is treated mainly with hormone therapy.
- Hormone-resistant prostate cancer has learned how to grow without using testosterone as its fuel. It’s treated with ADT and another type of therapy—often a newer hormone therapy or chemotherapy.
- Second hormone therapy is commonly added to ADT as a preferred treatment option for advanced prostate cancer.
- Prostate cancer and its treatment may cause you to feel frustration, anger, regret, despair, and uncertainty. Know that you can still find happiness after diagnosis and treatment.
Supportive care and other assistance

57 Supportive care
58 Financial concerns
59 Survivorship
59 Advance care planning
61 Key points
Supportive care addresses the symptoms and side effects of prostate cancer, as well as psychological, social, financial, and spiritual issues. Many resources are available to help you feel better and answer your questions.

The main concern for most patients with cancer is to find treatment that works. Having cancer is about more than just treatment, though. Cancer care can be a rollercoaster that includes many additional physical and emotional challenges. It’s important to know that you can get support for these challenges.

Supportive care is for relieving the symptoms of cancer, the side effects of cancer therapies, and other health issues related to the cancer. Supportive care also helps with psychological, social, and spiritual issues.

Supportive care is given at any stage of disease, not just at the end of life.

Supportive care involves the whole person, not just their cancer. Supportive care addresses many needs. It can help with making treatment decisions. It can also assist with coordinating care between health providers. Notably, supportive care can help prevent or treat physical and emotional symptoms. Supportive care can also help with financial support, advance care planning, and end-of-life concerns.

It’s important to talk openly with your treatment team about supportive care. Some medical centers have patient navigators or other staff members who coordinate nonclinical supportive care. Ask questions and reach out if you need more information about supportive care.

Anxiety and depression

Many people with prostate cancer experience symptoms of distress, such as anxiety and depression. You may feel anxious during testing, or you may experience depression during a hard part of treatment, or because your life is not the same as it was before cancer. Tell your treatment team if you’re experiencing these symptoms so that you can get help.

Report any unusual feelings of sadness, loss of interest in activities, anxiety, and sleep problems to your doctor. Many people experience these feelings, and they should not go untreated.”
Help can include support groups, talk therapy, or medication. At your cancer center, patient navigators, social workers, and other experts can help. Some people also feel better by exercising, talking with loved ones, or relaxing.

**Support groups**

Many people diagnosed with cancer find support groups to be helpful. A support group provides the opportunity to talk with others who are going through, or have been through, similar experiences. Support groups often include people at different stages of treatment. Some people may be newly diagnosed, while others may be finished with treatment. If your hospital or community doesn’t have support groups for people with cancer, have a look at the online resources listed on page 72 of this book.

**Financial concerns**

The financial cost of prostate cancer can be overwhelming. As a result, many people with prostate cancer and their loved ones struggle with the cost of treatment, as well as the stress of paying for it.

To make things worse, you may miss work during treatment or become unemployed. Or you may have trouble paying for or getting medicines. Or you may have too little or no health insurance.

If you struggle to pay for food, housing, treatment, follow-up care, and other expenses, or you have difficulty getting to appointments, talk with your care team’s social worker, patient navigator, and hospital financial services staff. They can help you find financial support and transportation options.

It’s important to ask for help

Depression, anxiety, fear, and distress are very common feelings for people with cancer. These feelings can make it harder to deal with cancer and cancer treatment. They can hold you back even when you want to move forward.

Getting help when you’re feeling worried or hopeless is an important part of cancer care. If you’re feeling anxious or overwhelmed, ask your treatment team for help.

More information about cancer and distress is available at [NCCN.org/patientguidelines](http://NCCN.org/patientguidelines) and on the [NCCN Patient Guides for Cancer](http://NCCN.org/patientguidelines) app.

You can also talk to your treatment team about work, health insurance, or money problems. Your team can include information in your treatment plan to help you manage your finances and medical costs. If your doctors and care providers don’t talk about how to pay for treatment, it’s okay for you to ask them about it first.
Survivorship

Survivorship focuses on the health and well-being of a person with cancer from diagnosis until the end of life. This includes the physical, mental, emotional, social, and financial effects of cancer that begin at diagnosis, continue through treatment, and arise afterward.

Survivorship also includes concerns about follow-up care, late effects of treatment, cancer recurrence, and quality of life. Support from family members, friends, and caregivers is also an important part of survivorship.

Read more about survivorship in NCCN Guidelines for Patients: Survivorship Care for Healthy Living and Survivorship Care for Cancer-Related Late and Long-Term Effects, available at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.

Consider quality of life

Quality of life is a term used often in cancer care. It refers to a person’s overall enjoyment of life, including their sense of well-being and ability to participate in regular activities. For some people, aggressive cancer treatment may extend their life but reduce their quality of life. That’s one reason why quality of life should be an important consideration when making decisions about cancer treatment.

Advance care planning

Advance care planning is for everyone, not just for those who are very sick. Advance care planning means deciding what care you would want if you become unable to make medical decisions for yourself. It’s about making sure that your wishes are understood and respected.

The focus is on you receiving the best possible care at the end of your life. Patients with incurable cancer can set up an advance care plan early to help them feel less stressed and better able to cope with their condition.

The advance care planning process starts with an open and honest discussion with your care team about your prognosis—what you may experience in the coming months—and the medications or therapies that may give
Advance care planning

Make your wishes clear. It’s important that everyone clearly understands the goals of your care and your personal wishes about what should—and should not—be done. You can decide if there is a point where you might want to stop cancer treatment. You can also decide what treatments you would want for symptom relief.

Once you’ve made these decisions, you’ll fill out a legal document that explains what you want to be done if you aren’t able to tell your care team yourself. This document is called an advance directive. Your health care providers are required to follow the instructions in an advance directive when you’re too ill to make decisions about your care.

Tell your care team and family about your advance directive and its contents. Give a copy of your advance directive to all your doctors. Make sure you give a copy to anyone you’ve authorized to make decisions on your behalf (health care proxy). If your family or loved ones disagree with your plan, speak to your care team. Sometimes they or other specialists can help you and your family navigate these difficult conversations.

You can change your advance care plan at any time. Frequent conversations with your care team can help.

End-of-life considerations

End-of-life care provides medical, psychological, and spiritual support for people who are close to the end of life as well as the people who love them. The goal is comfort, not a cure. It may also be called comfort care.
or hospice. Note that hospice is a special kind of end-of-life care. Hospice refers specifically to an insurance benefit for people whose life expectancy is 6 months or less. Hospice supports those at the end of life by bringing in additional care providers and resources such as home care.

The goal of end-of-life care is to give people the best life possible with the time they have left. Care can be provided in your home, a hospice facility, or even in the hospital. A major goal is to keep you pain-free and make sure that you can leave this world comfortably and with dignity. Hospice doctors, nurses, social workers, and chaplains are experts in helping patients work through the spiritual and emotional challenges of coping with the end of life.

Providing support for family members is a key part of hospice care. Most programs offer counseling and support groups for family members, including support after the patient has died. This is referred to as bereavement. It can be very comforting to know that your loved ones will have that kind of support after you’re gone.

Key points

- Supportive care is for relieving symptoms and side effects, and for other health issues related to cancer.
- Supportive care is given at any stage of disease, not just at the end of life.
- Supportive care is treatment that involves the whole person, not just their cancer.
- Many people with prostate cancer experience anxiety and depression. Help is available.
- A support group provides the opportunity to talk with others who’ve been through similar experiences.
- For help with financial support and transportation options, talk with your care team’s social worker, patient navigator, and hospital financial services staff.
- Advance care planning is done to ensure that your end-of-life wishes are understood and respected.

Be your own advocate. Talk to someone who has gone through the same thing as you. Ask a lot of questions, even the ones you are afraid to ask. You have to protect yourself and ensure you make the best decisions for you, and get the best care for your particular situation.”
7

Making treatment decisions

63  It’s your choice
64  Questions to ask
72  Resources
It’s important to be comfortable with the cancer treatment you choose. This choice starts with having an open and honest conversation with your care team about the benefits and risks of treatment.

It’s your choice

Treatment decisions are very personal. What’s important to you may not be important to someone else. In shared decision-making, you and your care team share information, discuss the options, and agree on a treatment plan. Be clear about your goals for treatment and find out what to expect from treatment. It starts with an open and honest conversation between you and your team.

Some things that may play a role in your decision-making:

- What you want and how that might differ from what others want
- Your religious and spiritual beliefs
- Your feelings about certain treatments like hormone therapy or radiation
- Your feelings about pain or side effects
- Cost of treatment, travel to treatment centers, and time away from school or work
- Quality of life and length of life
- How active you are and the activities that are important to you

Think about what you want from treatment. Discuss openly the risks and benefits of specific treatments and procedures. Weigh options and share concerns with your care team.

Second opinion

It’s normal to want to start treatment as soon as possible. While cancer treatment shouldn’t be ignored, there is usually time to have another cancer care provider review your test results and suggest a treatment plan. This is called getting a second opinion, and it’s a normal part of cancer care. Even doctors get second opinions!

Seek out a prostate cancer specialist, if you can, because they have experience diagnosing and treating a lot of people with your type of cancer.

Things you can do to prepare:

- Check with your insurance company about its rules on second opinions. There may be out-of-pocket costs to see providers who are not part of your insurance plan.
- Make plans to have copies of all your records and imaging scans sent to the doctor you will see for your second opinion.
Things to think about when making treatment decisions

Be sure to weigh all your options. There are no "correct" answers. The right decision is the one that's best for you. Consider:

<table>
<thead>
<tr>
<th>Your personal preferences</th>
<th>vs.</th>
<th>Your health care providers’ recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Having definitive treatment</td>
<td>vs.</td>
<td>Keeping other treatment options open</td>
</tr>
<tr>
<td>Length of life</td>
<td>vs.</td>
<td>Quality of life</td>
</tr>
<tr>
<td>Traveling for treatment</td>
<td>vs.</td>
<td>Staying close to home and family</td>
</tr>
<tr>
<td>Having more treatment</td>
<td>vs.</td>
<td>Having more side effects</td>
</tr>
<tr>
<td>Having standard treatment</td>
<td>vs.</td>
<td>Waiting for specialized treatment, which</td>
</tr>
<tr>
<td>(now, which is covered by your health plan)</td>
<td></td>
<td>requires your health plan’s approval</td>
</tr>
</tbody>
</table>

Questions to ask

Possible questions to ask your care providers are listed on the following pages. Feel free to use these or come up with your own. Have a notebook handy to jot down the answers to your questions.
Questions about cancer testing

1. What tests will I have?
2. Do the tests have any risks?
3. Will my health plan pay for all the tests you’re recommending?
4. Do I need to do anything to prepare for testing?
5. Should I bring someone with me to the appointments?
6. Where do I go for testing, and how long will it take?
7. If any of the tests will hurt, what will you do to make me comfortable?
8. How soon will I know the results and who will explain them to me?
9. How can I get a copy of the pathology report and other test results?
10. What is the cancer stage? What does this stage mean in terms of survival?
Questions about treatment choices

1. What are my treatment options?

2. Are you suggesting options other than what NCCN recommends? If yes, why?

3. What will happen if I do nothing?

4. Does any option offer a cure or long-term cancer control?

5. How do my age, family history, overall health, and other factors affect my options?

6. Will the treatment hurt?

7. How long do I have to decide about treatment? Is there a social worker or someone who can help me decide?

8. Is a clinical trial an option for me?

9. How do I get a second opinion?
Questions about what to expect

1. Does this hospital or cancer center offer the best treatment for me?

2. Do I have a choice of when to begin treatment?

3. How long will treatment last?

4. Will my insurance cover the treatment you’re recommending?

5. Are there any programs to help pay for treatment?

6. What supportive care and services are available to me and my caregivers?

7. Who should I contact with questions or concerns if the office is closed?

8. How will you know if treatment is working?

9. What are the chances of the cancer worsening or returning?

10. What follow-up care is needed after treatment?
Questions about side effects

1. What are the possible complications and side effects of treatment?
2. Which side effects are most common and how long do they usually last?
3. Which side effects are serious or life-threatening?
4. Are there any long-term or permanent side effects?
5. What symptoms should I report right away, and who should I contact?
6. Will treatment affect my ability to urinate? Or have an erection?
7. What can I do to prevent or relieve the side effects of treatment?
8. Do any medications worsen side effects?
9. Do any side effects lessen or worsen in severity over time?
10. Will you stop or change treatment if there are serious side effects?
Questions about your care team’s experience

1. Are you board certified? If yes, in what area?

2. What is your experience as well as your team’s experience with treating my type of prostate cancer?

3. How many patients like me (of the same age, race) have you treated?

4. Will you be consulting with experts to discuss my care? Who will you consult?

5. Is my treatment or procedure a major part of your practice? How often have you done this treatment or procedure in the last year?

6. How many of your patients have had complications? What were the complications?
Questions about clinical trials

1. Do you recommend that I consider a clinical trial for treatment?

2. How do I find clinical trials that I can participate in?

3. What are the treatments used in the clinical trial?

4. Has the treatment been used for other types of cancer?

5. What are the risks and benefits of this treatment?

6. What side effects should I expect and how will they be managed?

7. How long will I be in the clinical trial?

8. Will I be able to get other treatment if this doesn’t work?

9. How will you know if the treatment is working?

10. Will the clinical trial cost me anything?
Questions about resources and support

1. Who can I talk to about help with housing, food, and other basic needs?

2. What assistance is available for transportation, childcare, and home care?

3. Who can tell me what my options for health insurance are and assist me with applying for insurance coverage?

4. How much will I have to pay for my treatment? What help is available to pay for medicines and other treatment?

5. Who can help me with my concerns about missing work or school?

6. How can I connect with others and build a support system?

7. Who can I talk to if I don't feel safe at home, at work, or in my neighborhood?
Resources

**AnCan Foundation**
ancan.org

**Cancare**
Cancare.org

**CancerCare**
cancercare.org

**Cancer Hope Network**
cancerhopenetwork.org

**FORCE: Facing Our Risk of Cancer Empowered**
facingourrisk.org

**Imerman Angels**
imermanangels.org

**Malecare**
malecare.org

**National Alliance of State Prostate Cancer Coalitions (NASPCC)**
naspcc.org

**National Coalition for Cancer Survivorship**
canceradvocacy.org

**PCaAware National Prostate Cancer Awareness Foundation**
pcaaware.org

**Prostate Conditions Education Council (PCEC)**
prostateconditions.org

**Prostate Health Education Network (PHEN)**
prostatehealthed.org

**Triage Cancer**
triagecancer.org

**ZERO Prostate Cancer**
zerocancer.org
Words to know

**advanced-stage prostate cancer**
Prostate cancer that has spread beyond the prostate to other areas in the body. This includes regional and metastatic prostate cancer.

**androgen deprivation therapy (ADT)**
Hormone therapy that stops the body from making testosterone or blocks cancer cells from using testosterone. ADT can be given through drugs or surgery.

**anti-androgen**
A drug that stops the action of the hormone testosterone.

**biopsy**
A procedure that removes fluid or tissue samples to be tested for disease.

**castration**
Surgery that removes the testicles, or drugs that suppress the function of the testicles, to minimize testosterone levels.

**computed tomography (CT)**
An imaging test that uses x-rays from many angles to make a picture of the inside of the body.

**digital rectal exam**
An exam of the prostate by feeling it through the wall of the rectum.

**early-stage prostate cancer**
Prostate cancer that stays within the prostate and usually grows slowly.

**enlarged prostate**
An overgrowth of tissue in the prostate that isn't caused by cancer. Also called benign prostatic hyperplasia (BPH).

**erectile dysfunction**
A lack of blood flow to the penis that limits getting or staying erect.

**external beam radiation therapy (EBRT)**
A treatment in which a machine outside the body aims radiation precisely at cancer inside the body.

**genetic mutation**
A harmful change in the cell's instructions, which damages its function and can lead to disease.

**hormone therapy**
A cancer treatment that stops the making or action of hormones. Also called androgen deprivation therapy.

**life expectancy**
The number of years a person is likely to live based on statistics of other people in similar circumstances.

**luteinizing hormone-releasing hormone (LHRH) agonist**
A drug that acts in the brain to stop the testicles from making testosterone.

**luteinizing hormone-releasing hormone (LHRH) antagonist**
A drug that acts in the brain to stop the testicles from making testosterone.

**lymphatic system**
A network of organs and vessels that fights infections and transports a fluid called lymph.

**lymph nodes**
Small clusters found throughout the body that filter lymph fluid to remove germs.
magnetic resonance imaging (MRI)
A test that uses radio waves and powerful magnets to make pictures of the insides of the body.

metastasis
The spread of cancer from the site where it started to a new site in the body.

metastatic prostate cancer
Cancer that spreads beyond the prostate to other parts of the body.

observation
A period of watching for cancer occurrence or growth while not receiving treatment.

orchiectomy
An operation to reduce testosterone in the body by removing one or both testicles.

palliative therapy
Health care for the symptoms of cancer or the side effects of cancer treatment. Palliative therapy is an important part of supportive care.

pathologist
A doctor who specializes in testing cells and tissue to find disease.

pelvic lymph node dissection (PLND)
An operation that removes lymph nodes in the pelvis.

positron emission tomography (PET)
An imaging test that uses radioactive material to see the shape and function of body parts.

prostate-specific antigen (PSA)
A protein made by the prostate that helps semen transport sperm. PSA is measured in nanograms per milliliter of blood (ng/mL).

prostate-specific membrane antigen (PSMA)
A protein found on the surface of prostate cancer cells. PSMA is a biomarker of prostate cancer cells.

PSA persistence
When PSA level is still detectable after prostate cancer treatment.

PSA recurrence
When PSA level drops after prostate cancer treatment but then rises again.

radiation therapy
Treatment that uses high-energy rays (radiation) to kill cancer cells and stop new cancer cells from being made.

radical prostatectomy
An operation that removes the entire prostate as well as surrounding tissue, seminal vesicles, and sometimes nearby lymph nodes.

recurrence
The return of cancer after a disease-free period.

regional prostate cancer
Cancer that has grown from the prostate to neighboring areas, but no farther.

risk factor
Something that increases the chance of getting a disease.

seminal vesicles
Glands that make and store part of the fluid that becomes semen.

supportive care
Health care other than curative treatment that supports the physical, emotional, social, and spiritual needs of patients, families, and caregivers.
This patient guide is based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, Version 4.2024. It was adapted, reviewed, and published with help from the following people:

Dorothy A. Shead, MS  
Senior Director,  
Patient Information Operations

John Murphy  
Medical Writer

Susan Kidney  
Senior Graphic Design Specialist

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, Version 4.2024 were developed by the following NCCN Panel Members:

Edward M. Schaeffer, MD, PhD  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Sandy Srinivas, MD  
Stanford Cancer Institute

Nabil Adra, MD, MSc  
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Yi An, MD  
Yale Cancer Center/Smilow Cancer Hospital

*Rhonda Bitting, MD  
Duke Cancer Institute

*Brian Chapin, MD  
The University of Texas  
MD Anderson Cancer Center

*Heather H. Cheng, MD, PhD  
Fred Hutchinson Cancer Center

Anthony Victor D’Amico, MD, PhD  
Dana-Farber/Burnham and Women’s Cancer Center | Mass General Cancer Center

Neil Desai, MD, MHS  
UT Southwestern Simmons Comprehensive Cancer Center

Tanya Dorff, MD  
City of Hope National Cancer Center

James A. Eastham, MD  
Memorial Sloan Kettering Cancer Center

Thomas A. Farrington  
Prostate Health Education Network (PHEN)

Xin Gao, MD  
Dana-Farber/Burnham and Women’s Cancer Center | Mass General Cancer Center

Shilpa Gupta, MD  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Thomas Guzzo, MD, MPH  
Abramson Cancer Center  
at The University of Pennsylvania

Joseph E. Ippolito, MD, PhD  
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

R. Jeffrey Karnes, MD  
Mayo Clinic Comprehensive Cancer Center

Michael R. Kuettel, MD, MBA, PhD  
Roswell Park Comprehensive Cancer Center

Joshua M. Lang, MD, MS  
University of Wisconsin Carbone Cancer Center

Tamara Lotan, MD  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

*Rana R. McKay, MD  
UC San Diego Moores Cancer Center

Todd Morgan, MD  
University of Michigan Rogel Cancer Center

Julio M. Pow-Sang, MD  
Moffitt Cancer Center

Robert Reiter, MD, MBA  
UCLA Jonsson Comprehensive Cancer Center

Mack Roach, III, MD  
UCSF Helen Diller Family Comprehensive Cancer Center

Tyler Robin, MD, PhD  
University of Colorado Cancer Center

Stan Rosenfeld  
University of California San Francisco  
Patient Services Committee Chair Emeritus

Ahmad Shabsigh, MD  
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Daniel Spratt, MD  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Russell Szmulowitz, MD  
The UChicago Medicine Comprehensive Cancer Center

*Benjamin A. Teply, MD  
Fred & Pamela Buffett Cancer Center

Jonathan Tward, MD, PhD  
Huntsman Cancer Institute at the University of Utah

Richard Valicenti, MD  
UC Davis Comprehensive Cancer Center

Jessica Karen Wong, MD  
Fox Chase Cancer Center

* Reviewed this patient guide. For disclosures, visit NCCN.org/disclosures.

NCCN Guidelines for Patients®  
Advanced-Stage Prostate Cancer, 2024
We want your feedback!

Our goal is to provide helpful and easy-to-understand information on cancer.

Take our survey to let us know what we got right and what we could do better.

NCCN.org/patients/feedback
Index

androgen deprivation therapy (ADT) 25, 27–29, 39, 41, 44, 46–53, 55

biopsy 13, 15, 17–20, 42, 43

bone scan 15, 17

chemotherapy 10, 25, 28–30, 46, 48–53

clinical trial 32–34, 53–54

digital rectal exam 13–14

erectile dysfunction 27–28, 32, 40–41

 genetic testing 15, 20–22

hormone-resistant prostate cancer 29, 31, 47, 49–54

hormone-sensitive prostate cancer 47–49, 50

hormone therapy 10, 25–29, 32, 34, 38–39, 41, 43, 46–53, 63

immunotherapy 10, 25, 28–30, 46, 50–51

inherited gene testing 21

life expectancy 38–42, 61

metastasis 10, 15–18, 20–22, 31, 34, 38, 41, 43, 46, 48–49

pelvic lymph node dissection (PLND) 39, 43

prostate surgery (radical prostatectomy) 38–43

PSA persistence 42–44

PSA recurrence 16–17, 32, 35, 37, 42–44, 59


radiopharmaceutical 10, 30, 31, 46, 50, 53

regional prostate cancer 10, 21, 32, 36, 38–44, 46

risk factors 6, 8

sexual side effects 15, 27–28, 32, 35, 40–41

supportive care 34, 36, 53–54, 57–58

targeted therapy 10, 17, 22, 25, 28, 30–31, 46, 50–53

tumor, node, metastasis (TNM) system 22

tumor testing 21

ultrasound imaging 15, 17–9

urinary problems (incontinence) 6, 27, 32, 35, 40